Remove Biopharma Remove Leads Remove Safety Remove Side effects
article thumbnail

Leading speciality pharmacies in pharma

Pharmaceutical Technology

Speciality pharmacies play a crucial role in medication dosing, disease and side effects management, and patient care. Patient education and medication adverse effect counselling. Patient monitoring for safety and efficacy. The post Leading speciality pharmacies in pharma appeared first on Pharmaceutical Technology.

article thumbnail

Liver injuries prompt clinical hold on Sanofi BTK drug

pharmaphorum

billion buyout of Principia Biopharma has run into trouble, after the FDA placed it on partial clinical hold while a safety signal is investigated. Those changes haven’t been enough to prevent the FDA from taking action, although outside the US the studies will continue as planned with the tighter safety monitoring.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Drug repurposing, real world data and AI/ML: perspectives and opportunities

Clarivate

Drug candidates have a high rate of failure, as only 10% of de-novo drugs put through clinical trials finally obtain market approval, with the highest rate of attrition occurring at phase I and II of clinical trials (assessing safety, tolerability, dosage, efficacy, and side effects).

article thumbnail

The evolution of AAVs in cell and gene therapy

European Pharmaceutical Review

In June 2023, an array of leading voices in AAV development for cell and gene therapies articulated the current challenges and their optimism for the rapidly advancing sector at the Cell and Gene Therapy Summit event in London. For cell and gene therapy, a “big issue” she stated, was the complexity of manufacturing.

article thumbnail

Practical advice for Early Scientific Advice (ESA) in HTA submissions

pharmaphorum

In recent years, the biopharma market has become progressively complex. Payers must take into consideration not only the clinical efficacy of a drug, but also its safety profile, side effects, and cost-effectiveness, among other factors.

article thumbnail

The State of the Union in Cancer Innovation

PM360

However, due to conjugation instability and unfavorable safety profiles of currently available ADCs, we can still do more to ensure ADCs are more broadly available and amenable options for the patients who need them. What Other Developments Within Oncology Excite You? What Is Your Company Currently Working On?

article thumbnail

How to Work with Patient Advocates, Influencers, and Ambassadors

PM360

Then, the MRL team and the influencer must align on where there is flexibility within messaging while still abiding to brand safety guidelines, as you don’t want to lose the authenticity that the influencer brings. A Patient-Centric Month Leads to Results. For example, everyone must be steeped in both FDA and FTC guidelines.